Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IgG trough levels after switching from standard SCIG to every-other-week and 3–4-week HyQvia in primary immunodeficiency
2016-001480-36Phase 3Completed
- Sponsor
- CHU de Lille
- Start
- Nov 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Human normal immunoglobulin G in Immunogenetic disorder, sponsored by CHU de Lille. Primary endpoint: Change in IgG trough level at V3 compared to V1. Started Nov 2016; status: completed.
02
Drugs
Human normal immunoglobulin G
03
Conditions
Immunogenetic disorder
Beyond the preview
Go deeper on 2016-001480-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001480-36.